What is Roflumilast?
Roflumilast is an oral, selective phosphodiesterase‑4 (PDE4) inhibitor approved for use as a maintenance treatment in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. It works by reducing airway inflammation, thereby improving lung function and decreasing the frequency of COPD exacerbations.
Reference: U.S. Food and Drug Administration (FDA) Roflumilast Prescribing Information; World Health Organization (WHO) guidelines on COPD management
What are the other popular names for Roflumilast?
Roflumilast is marketed under several brand names, including:
- Daliresp® (widely used in the United States)
- Ariflo® (in some international markets)
Reference: U.S. FDA; ClinicalTrials.gov
What is the drug classification of Roflumilast?
Roflumilast is classified as an oral selective PDE4 inhibitor. It falls under the therapeutic category of anti-inflammatory agents for respiratory diseases, specifically used in the management of COPD.
Reference: U.S. FDA; World Health Organization (WHO)
What is the mode of action of Roflumilast?
Roflumilast works by inhibiting the enzyme phosphodiesterase‑4 (PDE4) in inflammatory cells. This inhibition increases intracellular cyclic adenosine monophosphate (cAMP) levels, which leads to:
- Reduced Release of Pro-inflammatory Mediators: Lowering cytokine production and inflammation in the airways.
- Improved Airflow: By reducing inflammation, it helps alleviate bronchoconstriction and improves lung function.
Reference: PubMed (e.g., studies on PDE4 inhibition in COPD); U.S. FDA
How is Roflumilast used?
Roflumilast is used as a maintenance treatment in patients with severe COPD, particularly in those with chronic bronchitis who are prone to frequent exacerbations. It is intended for long‑term use as part of a comprehensive treatment plan that may also include bronchodilators and other COPD therapies.
Reference: American Thoracic Society (ATS) guidelines; U.S. FDA; ClinicalTrials.gov
What is the recommended dosage and administration for Roflumilast?
- Dosage: The typical recommended oral dose is 500 µg once daily.
- Administration:
- Roflumilast should be taken once daily, with or without food, preferably at the same time each day.
- Consistent use is key to maintaining its anti‑inflammatory effect and improving lung function over time.
Reference: U.S. FDA Roflumilast Prescribing Information; ClinicalTrials.gov
What prescribing information is important for Roflumilast?
- Indications:
- Roflumilast is indicated for reducing the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis.
- Contraindications:
- Known hypersensitivity to roflumilast or any of its components.
- Not recommended for use in patients with moderate to severe liver impairment without careful consideration.
- Monitoring:
- Patients should have periodic liver function tests and assessments for potential psychiatric side effects.
- Special Considerations:
- Roflumilast should be used as part of a comprehensive COPD management plan.
- The drug is not intended for the immediate relief of acute bronchospasm.
Reference: U.S. FDA; WHO; National Institutes of Health (NIH) guidelines
What safety information, warnings, and cautions are associated with Roflumilast?
- Common Side Effects:
- Diarrhea, weight loss, nausea, headache, and insomnia.
- Warnings & Cautions:
- Psychiatric Effects: Roflumilast may be associated with mood changes, anxiety, or depression in some patients. Monitor for signs of psychiatric distress.
- Gastrointestinal Effects: Diarrhea and weight loss can occur; patients should be advised to maintain proper hydration and nutrition.
- Hepatic Function: There is a risk of liver enzyme elevation; liver function should be monitored periodically, especially in patients with preexisting liver conditions.
- Contraindications in Pregnancy: Roflumilast is contraindicated during pregnancy and lactation. Women of childbearing potential should use effective contraception.
Reference: U.S. FDA Roflumilast Prescribing Information; PubMed literature on PDE4 inhibitors; WHO
What drug interactions should be considered with Roflumilast?
- CYP3A4 Inhibitors:
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase plasma levels of roflumilast and its active metabolite, potentially enhancing adverse effects.
- Other Medications with Gastrointestinal Effects:
- Drugs that cause gastrointestinal upset may have additive effects when used with roflumilast.
- Hepatotoxic Agents:
- Caution is advised when roflumilast is used in patients receiving medications that can impair liver function.
Reference: U.S. FDA; Clinical Pharmacology Reviews on PubMed
Where can I find additional clinical evidence and detailed information about Roflumilast?
For further details on clinical studies, dosing, and safety monitoring, please refer to:
- U.S. Food and Drug Administration (FDA) Website: FDA.gov
- ClinicalTrials.gov: Search for roflumilast studies (e.g., NCT00910696)
- World Health Organization (WHO): COPD management guidelines
- PubMed: For peer‑reviewed research articles on roflumilast in COPD
Reference: U.S. FDA; WHO; PubMed
Final Thoughts
Roflumilast is an effective oral PDE4 inhibitor used to reduce the frequency of COPD exacerbations in patients with severe COPD and chronic bronchitis. By increasing cAMP levels in inflammatory cells, it diminishes airway inflammation and improves lung function. Due to its potential gastrointestinal and psychiatric side effects—and its interactions with certain CYP3A4 inhibitors—roflumilast should be prescribed with careful patient selection and monitoring. Always consult your healthcare provider to determine if roflumilast is the appropriate treatment as part of a comprehensive COPD management plan.
Disclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.
India
